SavedAdd your journal

Journals / Dicle Tıp Dergisi / 2022 / Cilt: 49 - Sayı: 2

Two cases of euglycemic diabetic ketoacidosis caused by dapagliflozin

Necla GÜNGÖRLER
Leyla SEYHAN
Zafer PEKKOLAY
Pages
385–389
Publication Date
2022-06-13
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Hyperglycemia (Glucose> 250 mg/dL), metabolic acidosis (pH

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hyperglycemia (Glucose> 250 mg/dL), metabolic acidosis (pH
📊
Key Findings & Data:Hyperglycemia (Glucose> 250 mg/dL), metabolic acidosis (pH
💡
Conclusion & Impact:Hyperglycemia (Glucose> 250 mg/dL), metabolic acidosis (pH
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Dapagliflozin · euglycemic ketoacidosis · sodium-glucose co-transporter 2 (SGLT-2) inhibitors

Abstract

Hyperglycemia (Glucose> 250 mg/dL), metabolic acidosis (pH

🔖

Cite This Article

GÜNGÖRLER, N., SEYHAN, L., PEKKOLAY, Z. (2022). Two cases of euglycemic diabetic ketoacidosis caused by dapagliflozin. Dicle Tıp Dergisi, Cilt: 49 - Sayı: 2, 385–389. https://ajindex.com/articles/484862

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Saeedi P, Petersohn I, Salpea P, et al. Global andregional diabetes prevalence estimates for 2019 andprojections for 2030 and 2045: Results from theInternational Diabetes Federation Diabetes Atlas.Diabetes Res Clin Pract. 2019
  2. 107843. 2.Nyenwe EA, Kitabchi AE. The evolution of diabeticketoacidosis: An update of its etiology, pathogenesisand management. Metabolism. 2016
  3. 65(4):507-21. 3.Dhatariya, K.K., Glaser, N.S., Codner, E. et al.Diabetic ketoacidosis. Nat Rev Dis Primers 6, 40 (2020). https://doi.org/10.1038/s41572-020-0165-1. 4. Plosker GL. Dapaglifozin: a review of its use in type 2 diabetes mellitus. Drugs. 2012
  4. 72(17):2289–312. 5.Sethi SM, Vohra M, Ali SA. Euglycemıc DıabetıcKetoacıdosıs (Edka) In A Patıent ReceıvıngDapaglıflozın. Acta Endocrinol (Buchar). 2021 Apr-Jun
  5. 17(2):266-9. 6.Rawla P, Vellipuram AR, Bandaru SS, Pradeep RJ.Euglycemic diabetic ketoacidosis: a diagnostic andtherapeutic dilemma. Endocrinol Diabetes MetabCase Rep. 2017
  6. 2017(1). 7.Danne T, Garg S, Peters AL, et al. InternationalConsensus on Risk Management of DiabeticKetoacidosis in Patients With Type 1 DiabetesTreated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care. 2019
  7. 42(6):1147-54. 8.Clar C, Gill JA, Court R, Waugh N. Systematicreview of SGLT2 receptor inhibitors in dual or tripletherapy in type 2 diabetes. BMJ Open. 2012 Oct18
  8. 2(5): e001007. 9.Liu J, Li L, Li S, Wang Y, Qin X, Deng K, Liu Y, Zou K,Sun X. Sodium-glucose co-transporter-2 inhibitorsand the risk of diabetic ketoacidosis in patients withtype 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2020 Sep
  9. 22(9):1619-27. 10.Peters AL, Buschur EO, Buse JB, et al. EuglycemicDiabetic Ketoacidosis: A Potential Complication ofTreatment With Sodium-Glucose Cotransporter 2Inhibition. Diabetes Care 2015
  10. Palmer BF, Clegg DJ, Taylor SI, Weir MR. Diabeticketoacidosis, sodium glucose transporter-2inhibitors and the kidney. J Diabetes Complications2016
  11. Ueda P, Svanström H, Melbye M, et al. Sodiumglucose cotransporter 2 inhibitors and risk ofserious adverse events: nationwide register basedcohort study. BMJ 2018
  12. k4365. 13. Moioli A, Maresca B, Manzione A, et al. Metformin associated lactic acidosis (MALA): clinical profilingand management. J Nephrol. 2016
  13. 29(6):783-789.doi: 10.1007/s40620-016-0267-8. 14.Nasa P, Chaudhary S, Shrivastava PK, Singh A.Euglycemic diabetic ketoacidosis: A misseddiagnosis. World J Diabetes. 2021 M